Rose Hip Powder Effective For Osteoarthritis Relief

[Guest guest]

Herbs for Health Article Joint Mobility Osteoarthritis Rose hip ( canina) Date: November 15, 2005 Re: Efficacy of Standardized Rose-hip Powder Hyben Vital on Joint Mobilitiy, Pain, and Daily Living Activities in Osteoarthritic Patients Elsabagh S, Hartley D, Ali O, on E, File S. Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers. Psychopharmacology. 2005;179:437-446. Pain associated with osteoarthritis (OA) is commonly treated in conventional medicine with nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids. However, the prolonged use of these drugs is associated with undesirable side effects. Although

conventional drugs called cyclooxygenase-2 (COX-2) inhibitors (enzymes involved in the synthesis of pro-inflammatory cytokines) have previously shown promising analgesic and anti-inflammatory activities, they have recently shown to produce serious side effects in some patients. And, these drugs are relatively expensive. Thus, there is a growing demand for safe, effective, low cost treatments for OA. The results of uncontrolled trials have shown analgesic activities of standardized rose-hip powder made from the seeds and fruit of a subtype of canina (subtype Lito). A powder extract of this plant was shown to inhibit leukocyte functions that result in cell injury in OA. The objective of this study was to evaluate the safety and efficacy of a standardized rose-hip powder (Hyben Vital® or Litozin®; [Hyben Vital International, Langeland, Denmark) on knee and hip joint mobility, pain, and activities of daily living (ADLs) in patients with osteoarthritis.A single-center,

double-blind, randomized, placebo-controlled study was conducted in 100 patients (n = 65 women and 35 men) aged 65.2 ± 11.1 years with osteoarthritis of the hip or knee. The patients were randomly assigned in groups of 10 to receive either 500 mg capsules of the Hyben Vital special rose-hip powder (n = 50) or identical placebo (n = 50) twice daily (2000 mg/day for the Hyben Vital groups) for 4 months. The primary outcome measure was mobility of the knee (maximum flexion) and hip (maximum flexion and full range of internal and external rotation) joints, which was measured in both groups at baseline and after 4 months of treatment. Secondary outcome measures were pain and the ability to perform ADLs. Joint pain was assessed by the patients after 1, 2, and 4 months of treatment by responding to a simple yes-or-no questionnaire and after 4 months of treatment according to a 5-point scale, in which 0 represented "no improvement" and 5 represented "almost total relief of pain." At

baseline and after 1, 2, and 4 months of treatment, the patients recorded any difficulties they experienced in performing ADLs (e.g., walking, getting into and out of a car, shopping, and getting up and down from the lavatory). Compliance was assessed on the basis of the number of capsules returned unused by the patients, and any adverse events experienced were recorded. The rose-hip group showed significant improvements in passive hip flexion (P = 0.03), external hip rotation (P = 0.006), and internal hip rotation (P < 0.001) after 4 months of treatment. The placebo group showed significant improvements in passive internal hip rotation only (P = 0.031). Of these outcome measures, only the improvement in passive hip flexion was significantly different between the 2 groups. Improvement in passive knee flexion did not differ significantly between the 2 groups; the mean (±SD) improvement was 2.71 degrees ± 4.42 degrees (P = 0.012) in the rose-hip group and 3.75 degrees ±

5.32 degrees (P = 0.005) in the placebo group. Per the 5-point rating scale, relief from joint pain was significantly greater in the rose-hip group than in the placebo group after 4 months of treatment (P = 0.035).Per the yes-or-no questionnaire, significantly more patients in the rose-hip group than in the placebo group indicated relief from pain at 1 month (P = 0.014) and 4 months (P = 0.046) but not after 2 months of treatment. Changes in difficulties performing ADLs did not differ significantly between the 2 groups. However, significant improvements in several ADLs were observed in the placebo group after 1 and 2 months of treatment but not after 4 months of treatment. Furthermore, significant improvements in several ADLs were observed after 1, 2, and 4 months of treatment in the rose-hip group. Compliance was 98% in the rose-hip group and 97% in the placebo group. Mild gastrointestinal comfort was the only adverse event reported and was reported by only 2 patients in

each group.The results indicate that the functional capacity of the hip increased significantly and pain decreased significantly, with virtually no adverse side effects, after treatment with the standardized rose-hip powder. Despite these positive results, the authors state that "the clinical benefit of 4 months of treatment [with standardized rose-hip powder] should not be overestimated" and that "future research should include long-term studies to evaluate joint mobility, clinical improvements, and consumption of NSAIDs and other types of concomitant pain-reducing medicine." The authors state that it will also be important to identify the active ingredients in rose hip and to clarify whether the contents of such vary among subtypes of this plant. Research in this area has focused on a galactolipid compound called GOPO which is the putative active compound in the rosehip subtype that has shown anti-inflammatory activity.

Suzi

What is a weed? A plant whose virtues have not yet been discovered.

health/

www.onegrp.com/?mamanott organic cosmetics

http://suziesgoats.wholefoodfarmacy.com/

Music Unlimited - Access over 1 million songs. Try it free.